<?xml version='1.0' encoding='utf-8'?>
<document id="15212172"><sentence text="Pharmacokinetic analysis of ramatroban using a recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference in Sprague-Dawley and Eisai hyperbilirubinemic rats."><entity charOffset="28-38" id="DDI-PubMed.15212172.s1.e0" text="ramatroban" /></sentence><sentence text="The aim of this study was to characterize the in vivo pharmacokinetics with the enterohepatic circulation (EHC) and identify the role of multidrug resistance-associated protein 2 (MRP2/Mrp2) in biliary excretion and absorption of ramatroban, a thromboxane A2 antagonist using a recirculatory model"><entity charOffset="230-240" id="DDI-PubMed.15212172.s2.e0" text="ramatroban" /></sentence><sentence text="" /><sentence text="Ramatroban was intravenously or orally administered to Sprague-Dawley rats (SDR) and Eisai hyperbilirubinemic rats (EHBR)"><entity charOffset="0-10" id="DDI-PubMed.15212172.s4.e0" text="Ramatroban" /></sentence><sentence text=" Portal and systemic blood and bile samples were collected, and the drug concentrations were analyzed by high-performance liquid chromatography (HPLC) to estimate various global and local moments" /><sentence text="" /><sentence text="The bioavailability (BA) of ramatroban was estimated at 21"><entity charOffset="28-38" id="DDI-PubMed.15212172.s7.e0" text="ramatroban" /></sentence><sentence text="0% in SDR and 61" /><sentence text="9% in EHBR" /><sentence text=" The local absorption ratio for the dosage after oral administration (Fa(dosage)) and the single-pass local absorption ratio for EHC (Fa') in the rats were similar and nearly 100%" /><sentence text=" The hepatic recovery ratio (Fh) and the single-pass biliary excretion ratio through the liver for the sum of ramatroban and its glucuronides (Fb) in EHBR were 61"><entity charOffset="110-120" id="DDI-PubMed.15212172.s11.e0" text="ramatroban" /><entity charOffset="129-141" id="DDI-PubMed.15212172.s11.e1" text="glucuronides" /><entity charOffset="143-145" id="DDI-PubMed.15212172.s11.e2" text="Fb" /><pair ddi="false" e1="DDI-PubMed.15212172.s11.e0" e2="DDI-PubMed.15212172.s11.e0" /><pair ddi="false" e1="DDI-PubMed.15212172.s11.e0" e2="DDI-PubMed.15212172.s11.e1" /><pair ddi="false" e1="DDI-PubMed.15212172.s11.e0" e2="DDI-PubMed.15212172.s11.e2" /><pair ddi="false" e1="DDI-PubMed.15212172.s11.e1" e2="DDI-PubMed.15212172.s11.e1" /><pair ddi="false" e1="DDI-PubMed.15212172.s11.e1" e2="DDI-PubMed.15212172.s11.e2" /></sentence><sentence text="4% and 8" /><sentence text="88%, respectively, which differed considerably from those in SDR (15" /><sentence text="0% and 22" /><sentence text="4%)" /><sentence text=" The difference in hepatic elimination between these strains would be caused, at least in part, by the reduced biliary excretion in EHBR, although the biliary excretion was not completely impaired" /><sentence text="" /><sentence text="Ramatroban may be excreted by multiple transport systems, followed by efficient enterohepatic reabsorption in both strains"><entity charOffset="0-10" id="DDI-PubMed.15212172.s18.e0" text="Ramatroban" /></sentence><sentence text=" The results suggest that ramatroban may not be susceptible to drug-drug interaction involving MRP2/Mrp2 in biliary excretion and absorption"><entity charOffset="26-36" id="DDI-PubMed.15212172.s19.e0" text="ramatroban" /></sentence><sentence text="" /></document>